Tag Archives: BIO Investor Forum

2012 BIO Investor Forum: Presenting Companies Making News

san-fran

Need a heart valve? Perhaps a bit more cartilage in your knees? Better yet, how about new blood vessels to bypass the old blocked ones? Amazingly, the days of relying upon animal or human cadavers’ tissue grafts to address these medical needs may possibly be drawing to a close. This is not Star Trek and this is not the Walt Disney’s optimistic science of Tomorrowland. As detailed in the Wall Street Journal last week, medical Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

A Start-Up Model Worthy of Consideration

attendessBusinessForum

Biotech LLCs are getting a lot of attention lately, and perhaps rightfully so. The Wall Street Journal’s Brian Gormley recently talked to Albert L. Sokol, a partner with Edwards Wildman Palmer, about the two venture-backed biotechs – Forma Therapeutics and Viamet Pharmaceuticals – that he helped convert to LLCs. In the WSJ article – Biotech Start-Ups See Benefits from Changing Structure, Lawyer Says – Sokol describes the benefits to start-ups and their venture investors, as Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

#BIF2012 Company Snapshot: ContraFect Corporation

ContraFect

The BIO Investor Forum is fast approaching! Below you’ll find our first Company Snapshot of one of the event’s presenting companies, ContraFect Corporation. Continue reading to learn more about ContraFect’s product, their strategies, and what you can expect from their company in the coming months. Company Snapshot What is your company’s lead product or technology? ContraFect is a private company developing biotherapeutics for resistant, life threatening infections. Our lead compound, CF-301, is a bacteriophage lysin, Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

2012 BIO Investor Forum: Looking Ahead to Investment Opportunities

partnering1

The biggest biotech news out of Washington in recent months was the Jumpstart Our Business Startups (JOBS) Act, which passed Congress overwhelmingly and was signed into law by President Obama in April.  For those not familiar, the JOBS Act creates a new category of issuers, called “emerging growth companies” (EGCs), which is defined as newly public companies with than $1 billion in annual revenues and a public float below $700 million. EGCs are given a Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

2012 Fall Event Preview

agenda

The 2012 BIO International Convention, the global event for biotechnology, held at the Boston Convention & Exhibition Center in Boston, Mass., wrapped this June. The event hosted a record 25,291 partnering meetings and highlighted a broad array of top-level speakers addressing critical global challenges and the top issues in biotechnology. Hosted by the Biotechnology Industry Organization (BIO), the event drew 16,505 industry leaders from 49 states and 65 countries. See what BIO President and CEO Jim Greenwood Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,